Researchers at the Medical University of South Carolina have identified a pathway that can be targeted by drugs to reduce fat accumulation in patients with metabolic dysfunction-associated fatty liver disease using a novel stem cell platform. They found that a common genetic mutation in patients with the disease leads to increased fat accumulation in liver cells. By screening compounds, they discovered that cancer drugs targeting this pathway could reduce fat accumulation in liver cells effectively. This study offers hope for a potential pharmaceutical treatment for this condition, utilizing already-approved drugs, and highlights the therapeutic potential of induced pluripotent stem cells in modeling and screening diseases.
Source link
A promising new therapeutic target for MASLD identified
